Freedom Capital Markets Upgrades Alnylam Pharmaceuticals to Buy, Lowers Price Target to $410

Alnylam Pharmaceuticals, Inc -3.98%

Alnylam Pharmaceuticals, Inc

ALNY

320.13

-3.98%

Freedom Capital Markets analyst Ilya Zubkov upgrades Alnylam Pharmaceuticals (NASDAQ: ALNY) from Hold to Buy and lowers the price target from $470 to $410.